BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

Blood

Volumn 118, Issue 12, 2011, Pages 3419-3425

  Visani, Giuseppe ^a   Malerba, Lara ^a   Stefani, Pietro Maria ^b   Capria, Saveria ^c   Galieni, Piero ^d   Gaudio, Francesco ^e   Specchia, Giorgina ^e   Meloni, Giovanna ^c   Gherlinzoni, Filippo ^b   Giardini, Claudio ^a   Falcioni, Sadia ^d   Cuberli, Francesca ^f   Gobbi, Marco ^f   Sarina, Barbara ^g   Santoro, Armando ^g   Ferrara, Felicetto ^h   Rocchi, Marco ⁱ   Ocio, Enrique M ^j   Caballero, Maria Dolores ^j   Isidori, Alessandro ^a  

^a Marche Nord Hospital   (Italy)

^b CA FONCELLO HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Hematology   (Italy)

^e UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ UNIVERSITY OF URBINO   (Italy)

^j CSIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN;

ADULT; AGED; ANAPLASTIC B CELL LYMPHOMA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B FOLLICULAR LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RESISTANT RELAPSED LYMPHOMA; T CELL RICH B CELL LYMPHOMA;

EID: 80053185604     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-351924     Document Type: Article

References (42)

1. Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009:497-506.
2. Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol. 2005;23(7):1522-1529.
3. Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol. 2005;130(3):363-372. (Pubitemid 43899584)
4. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non- Hodgkin's lymphoma. N Engl J Med. 1993; 328:1002-1006. (Pubitemid 23095683)
5. Bierman PJ, Armitage JO. Looking back (and ahead) at salvage treatment for non-Hodgkin lymphoma. Oncology (Williston Park). 2009;23(7): 619-625.
6. Seshadri T, Kuruvilla J, Crump M, Keating A. Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2008;14:259-267. (Pubitemid 351218193)
7. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with highdose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-2071. (Pubitemid 34680969)
8. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone-marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987; 316(24):1493-1498. (Pubitemid 17076232)
9. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 1995;13(3):588-595.
10. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non Hodgkin's lymphoma. N Engl J Med. 1995;333(23):1540-1545.
11. van Besien K, Tabocoff J, Rodriguez M, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen related toxicity. Bone Marrow Transplant. 1995;15:549-555.
12. Gribben JG, Linch DC, Singer CR, et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989; 73:340-344. (Pubitemid 19040999)
13. Fernandez HF, Escalon MP, Pereira D, Lazarus HM. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant. 2007;40: 505-513. (Pubitemid 47382119)
14. Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20:451-458. (Pubitemid 27434892)
15. Weaver CH, Petersen FB, Appelbaum FR et al. High-dose fractionated total- body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol. 1994;12:2559-2566. (Pubitemid 24379639)
16. Salar A, Sierra J, Gandarillas M, et al. GEL/TAMO Spanish Cooperative Group. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant. 2001;27:405-412. (Pubitemid 32201349)
17. Jo JC, Kang BW, Jang G, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008;87(1):43-48. (Pubitemid 350182540)
18. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14(1):309-317. (Pubitemid 351378007)
19. Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocitic leukemia (CLL): a multicenter phase II trial of the German CLL study group [abstract]. Blood. 2008;112. Abstract 130.
20. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23(15):3383-3389.
21. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(27):4473-4479.
22. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26(2):204-210.
23. Carvajal-Vergara X, Tabera S, Montero JC, et al. Multifunctional role of Erk5 in multiple myeloma. Blood. 2005;105(11):4492-4499. (Pubitemid 40720799)
24. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
25. Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumours. Br J Cancer. 2007; 96(11):1692-1698. (Pubitemid 46847200)
26. Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs. 2007;18(5): 587-595. (Pubitemid 46597413)
27. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
28. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the Rituximab era. J Clin Oncol. 2010;28(27):4184-4187.
29. Kewalramani T, Zelenetz AD, Nimer SD. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed primary refractory diffuse large B-cell lymphoma. Blood. 2004;103:3684-3688. (Pubitemid 38596282)
30. Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant. 2011;17(1):20-47.
31. Reece DE, Barnett MJ, Shepherd JD, et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood. 1995;86(2):451-456.
32. Reece DE, Nevill TJ, Sayegh A, et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant. 1999;23(11):1131-1138. (Pubitemid 29259669)
33. Seiden MV, Elias A, Ayash L, et al. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimen. Bone Marrow Transplant. 1992; 10:57-63.
34. Cao TM, Negrin RS, Stockerl-Goldstein KE, et al. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000;6:387-394.
35. Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant. 2000;25:309-313. (Pubitemid 30103021)
36. Bhatia S, Robinson LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic- cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. 2005; 105(11):4215-4222. (Pubitemid 40720765)
37. Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin's lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide and etoposide preparative regimen. Biol Blood Marrow Transplant. 2006;12:770-777. (Pubitemid 43899416)
38. Kim JG, Sohn SK, Chae YS, et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2007;40(10):919-24. (Pubitemid 350048188)
39. Yusuf RZ, Dey B, Yeap BY, et al. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2009;43(1):37-42.
40. Escalón MP, Stefanovic A, Venkatraman A, et al. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant. 2009;44(2):89-96.
41. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616-623. (Pubitemid 32113392)
42. Oehler-Jänne C, Taverna C, et al. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study. Hematol Oncol. 2008;26(2):82-90. (Pubitemid 351951336)